The chapter explores the development of a new form of MDMA for treating PTSD, examining the company involved, controversies, and challenges in clinical trials. It discusses the urgent need for solutions amidst the large number of PTSD sufferers, the therapy involved, and the FDA's review of this innovative treatment. The conversation also delves into the debate on the drug's effectiveness without the ecstatic experience, current limitations in PTSD treatments, and the investment landscape in biotech companies.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode